GADD45A, A POTENTIAL MOLECULAR MARKER IN SEROUS EPITHELIAL OVARIAN CANCER

ovarian cancer is the 4th leading cause of cancer-related death in women. In order
to reduce its mortality and morbidity, identification and evaluation of specific diagnostic biomarkers are
necessary. Given the importance of the GADD45A role in cell survival and death, its expression changes
were investigated in benign, borderline and malignant ovarian serous tumors in the present work.
Materials & Methods: Fresh specimens from different types of ovarian serous tissues including 75
tumors and 20 normal gathered from patients who referred to Urmia Kosar and Tabriz Alzahra hospitals
between 2015 and 2017 and stored in -80°C. After making a diagnosis by a pathologist, RNA extraction
was performed with TRIzol kit, cDNA was synthesized by Takara kit and then the GADD45A gene
expression was evaluated by Real-Time PCR
Results: The analysis revealed that GADD45A gene expression level showed a significant difference
between malignant and normal tissue (p<0.0001). In addition, we found a significant reduction trend in
expression of the GADD45A gene from benign to borderline to malignant tumors.
Conclusion: Based on our findings, it has been shown that the GADD45A gene expression level
significantly reduced in cancer samples. Therefore, this gene expression level may be used to identify
the disease stage in ovarian serous tumors. In addition, its expression level can be considered as a target
in cancer therapy